Evidence map›Paper›PMID 38279322›Full record

ReviewInternational journal of molecular sciences2024

Ignacio Goyache, Deyan Yavorov-Dayliev, Fermín I Milagro, Paula Aranaz

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Microorganisms · 2026
    Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Postbiotic pA1cInternational journal of molecular sciences · 2025
    Article
  8. Review
  9. Review
  10. Anti-Obesity Properties of a Novel Probiotic Strain ofInternational journal of molecular sciences · 2025
    Article
  11. Article
  12. Current research in food science · 2025
    Article
  13. A comprehensive approach, based on the use ofCurrent research in food science · 2025
    Article
  14. Review
  15. Drug target insights
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Ignacio GoyacheFaculty of Pharmacy and Nutrition, Department of Nutrition, Food Sciences and Physiology, University of Navarra, 31008 Pamplona, Spain.
Deyan Yavorov-DaylievFaculty of Pharmacy and Nutrition, Department of Nutrition, Food Sciences and Physiology, University of Navarra, 31008 Pamplona, Spain.ORCID 0000-0002-7901-0695
Fermín I MilagroFaculty of Pharmacy and Nutrition, Department of Nutrition, Food Sciences and Physiology, University of Navarra, 31008 Pamplona, Spain.ORCID 0000-0002-3228-9916
Paula AranazFaculty of Pharmacy and Nutrition, Department of Nutrition, Food Sciences and Physiology, University of Navarra, 31008 Pamplona, Spain.ORCID 0000-0002-1282-0079
Universidad de Navarra · ESNavarre Institute of Health Research · ESSpanish Biomedical Research Centre in Physiopathology of Obesity and Nutrition · ES

Funding

Gobierno de Navarra 0011-1383-2022- 411 000015
6 · The paper itself

Abstract

There is a growing need to develop new approaches to prevent and treat diseases related to metabolic syndromes, including obesity or type 2 diabetes, that focus on the different factors involved in the pathogenesis of these diseases. Due to the role of gut microbiota in the regulation of glucose and insulin homeostasis, probiotics with beneficial properties have emerged as an alternative therapeutic tool to ameliorate metabolic diseases-related disturbances, including fat excess or inflammation. In the last few years, different strains of bacteria, mainly lactic acid bacteria (LAB) and species from the genus

Indexed as

Diabetes Mellitus, Type 2Metabolic SyndromeProbioticsAnimalsCaenorhabditis elegansObesitycardiovascular diseasediabetesgut microbiotainsulin resistanceobesitypostbiotics

Identifiers

PMID38279322
PMCPMC10816037
OpenAlexW4391106248

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.